替诺福韦联合拉米夫定治疗乙型肝炎病毒/人类免疫缺陷病毒共感染患者的效果

Abstract
Figure/Table
References (15)
Related Citation (10)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Tenofovir combined with Lamivudine in the treatment of coinfection of Hepatitis B virus(HBV)and Human immunodeficiency virus(HIV).Methods Sixty patients with HIV/HBV admitted to our hospital from January 2014 to December 2016 were selected as subjects and divided into the control group(n=30)and the study group(n=30)according to the random number table method.The control group was treated with Lamivudine,while the study group was treated with Tenofovir on the basis of the control group.The HIV-RNA load,HBV-DNA load,CD4+T lymphocyte level,immunoglobulin level,liver function related indicators and adverse reactions were compared between the two groups after treatment.Results The rate of HIV-RNA below the lower limit and HBV-DNA below the lower limit in the study group were significantly higher than those in the control group,and the differences were statistically significant(P＜0.05).The CD4+T lymphocytes of the study group was (238.46±26.48)per 1 μl,which was significantly higher than that of the control group ([164.32±12.44]per 1 μl),and the difference was statistically significant(t=7.452,P＜0.05).The immunoglobulin level of the study group was significantly higher than that of the control group,and the difference was statistically significant(P＜0.05).The levels of alanine transaminase (ALT)and aspartate aminotransferase (AST)in the study group were significantly lower than those in the control group,and the differences were statistically significant(P＜0.05).There were no significant differences in levels of total bilirubin(TBIL)between two groups(P＞0.05).There was no significant difference in the total incidence of adverse reactions between two groups(P＞0.05).ConclusionTenofovir combined with Lamivudine in the treatment of patients with HIV and HBV can significantly reduce the viral load in the body and improve the immune function and liver function,with safe and effective clinical application.

Key words： Hepatitis B virus Human immunodeficiency virus Tenofovir Lamivudine Viral load

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Hua-min
	FANG Gui-hua
	DENG Qiao-juan

Cite this article:

ZHANG Hua-min,FANG Gui-hua,DENG Qiao-juan. Effect of Tenofovir combined with Lamivudine in the treatment of patients with Hepatitis B virus/Human immunodeficiency virus co-infection[J]. 中国当代医药, 2018, 25(23): 172-174.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I23/172

[1]	刘燕芬，黄绍标.两种干预模式对替诺福韦-拉米夫定、依非韦伦方案抗病毒治疗疗效影响的评价[J].世界复合医学，2016，2（1）：8-11.
[2]	中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南（2011 版）[J].中华传染病杂志，2011，29（10）：321-330.
[3]	中华医学会肝病学分会.慢性乙型肝炎防治指南（2010年版）[J].中国医学前沿杂志（电子版），2011，3（1）：1-12.
[4]	李繁，谢睿彬，李远，等.替诺福韦/拉米夫定/依非韦伦联合治疗老年HIV/AIDS疗效分析[J].右江民族医学院学报，2016，38（5）：493-495.
[5]	陈昭云，李自钊，赵清霞，等.HIV合并HBV感染的患者抗病毒治疗效果分析[J].中国艾滋病性病，2016，22（10）：776-778.
[6]	袁子清，叶珺.克力芝联合方案治疗HIV/AIDS患者的临床疗效分析[J].中国热带医学，2016，16（6）：601-604.
[7]	吴亚松，邓晓军，张伟伟，等.基于拉米夫定的治疗方案对HIV/HBV合并感染者HBV耐药的影响[J].中国艾滋病性病，2016，22（6）：407-409.
[8]	田雅茹，吴昊.HIV感染者合并乙型肝炎病毒感染的研究进展[J].医学研究杂志，2016，45（9）：164-167.
[9]	徐建明，李兵，游红勇，等.恩替卡韦联合替诺福韦与恩替卡韦联合阿德福韦治疗拉米夫定耐药性慢性乙型肝炎患者疗效比较[J].检验医学与临床，2016，13（13）：1788-1791.
[10]	刘胜昔.替诺福韦与拉米夫定联合治疗艾滋病合并乙型肝炎病毒72周疗效观察 [J].现代中西医结合杂志，2017， 26（9）：992-994.
[11]	卢新，杨海珊，刘道洁，等.抗病毒治疗对69例HIV合并HBV感染者肝功能和HBV病毒特征的影响[J].中国医药导报，2016，13（19）：42-46.
[12]	刘胜昔.替诺福韦与拉米夫定联合治疗艾滋病合并乙型肝炎病毒感染疗效观察[J].河北医药，2017，39（4）：589-591.
[13]	高化国.替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染分析[J].系统医学，2016，1（8）：54-56.
[14]	周艳.替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的效果观察[J].河南医学研究，2016，25（4）：746-747.
[15]	尹盛才.替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的临床效果分析[J].医学理论与实践，2017，30（20）：3045-3046.